Minerva Biotechnologies and iPS Academia Japan, Inc. announced recently that they have signed an agreement granting Minerva worldwide rights to use and commercialize the induced Pluripotent Stem (iPS) cells patent portfolio arising from the work of Professor Shinya Yamanaka, MD, Ph.D., who won the Nobel Prize for Medicine in 2012 for his discovery of four genes that can reprogram an adult’s cell to go back in time to become that person’s own stem cell